MONMOUTH JUNCTION, NJ--(Marketwired - August 14, 2013) - CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company working to save lives through blood purification, today announced that management will host a shareholder update conference call on Wednesday, August 21st at 4:15 p.m. Eastern. Management kindly asks all interested participants to submit their questions to Alliance Advisors at firstname.lastname@example.org.
Conference Call Details:
Date: Wednesday, August 21, 2013
Time: 4:15 p.m. Eastern
Participant Dial-In: (480) 629-9712
Live Webcast: http://public.viavid.com/index.php?id=105816
Submit Questions to: email@example.com
It is recommended that participants dial in approximately 10 minutes prior to the start of the 4:15 p.m. Eastern call. There will also be a simultaneous live webcast of the conference call which can be accessed through the following audio feed link and archived recording of the conference call available under the Investor Relations section of the company website at http://public.viavid.com/index.php?id=105816.
About CytoSorbents Corporation
CytoSorbents is a critical care focused therapeutic device company specializing in blood purification. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist. The goal of CytoSorb® is to prevent or treat multiple organ failure, the cause of nearly half of all deaths in the intensive care unit, with little available to improve clinical outcome. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: www.cytosorbents.com